Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
12/2005
12/15/2005WO2005118166A2 Pharmaceutical composition containing irbesartan
12/15/2005WO2005118009A2 Transdermal delivery system for treatment of cognitive disorders
12/15/2005WO2005117995A1 Application of hyaluronic acid to sentinel lymph node identification
12/15/2005WO2005117982A1 Ocular formulations with neuroprotectants to reduce alzheimer and neurotoxic risks created by large zinc dosages
12/15/2005WO2005117958A1 Vaccine compositions comprising virosomes and a saponin adjuvant
12/15/2005WO2005117949A1 Stabilized interferon liquid formulations
12/15/2005WO2005117948A1 Method of stabilizing proteins
12/15/2005WO2005117946A1 Treatment of amyotrophic lateral sclerosis
12/15/2005WO2005117942A2 Methods for encapsulation of biomacromolecules in polymers
12/15/2005WO2005117934A1 Sustained release composition
12/15/2005WO2005117921A1 Oral form of administration containing probiotic bacteria
12/15/2005WO2005117920A1 Agent for removing factor causing circulatory dysfunction
12/15/2005WO2005117905A2 Systems and methods for treating panic attacks
12/15/2005WO2005117901A1 Oral formulations of paricalcitol
12/15/2005WO2005117899A1 Pharmaceutical composition comprising tibolone and process for procuding the same
12/15/2005WO2005117896A1 Formulations containing fasudil, a matrix and an envelope
12/15/2005WO2005117886A1 Adhesive patch
12/15/2005WO2005117878A1 Irinotecan preparation
12/15/2005WO2005117850A1 Partially-fluorinated ethers, compositions and uses thereof, for long-term tamponade in the eye
12/15/2005WO2005117845A1 Oral preparations and process for production thereof
12/15/2005WO2005117844A2 Mucoadhesive nanocomposite delivery system
12/15/2005WO2005117843A2 Sustained release preparations
12/15/2005WO2005117842A2 Decontaminant edible product, methods of production and uses thereof
12/15/2005WO2005117841A1 Coated tablet formulation and method
12/15/2005WO2005117840A1 Stable pharmaceutical compositions comprising pulverized granules of nateglinide of form b
12/15/2005WO2005117839A1 Preparation of stable paroxetine hci er tablets using a melt granulation process
12/15/2005WO2005117838A1 Stable oral pharmaceutical compositions of buprenorphine and derivatives
12/15/2005WO2005117837A1 Process for preparation of amorphous form of a drug
12/15/2005WO2005117836A2 Polymeric microbeads having characteristics favorable for bone growth, and process including three dimensional printing upon such microbeads
12/15/2005WO2005117835A1 Fish-attractant product and methods of making and using it
12/15/2005WO2005117834A1 Solid dispersions of a basic drug compound and a polymer containing acidic groups
12/15/2005WO2005117833A2 Methods for dose selection of liposomal encapsulated sn38
12/15/2005WO2005117832A1 Liposomal assembly for therapeutic and/or diagnostic use
12/15/2005WO2005117830A1 Liquid depot formulations
12/15/2005WO2005117829A2 Chewable, suckable and swallowable tablet containing a calcium-containing compound as an active substance
12/15/2005WO2005117814A1 Duplex coated color lake and other powders, their preparation and cosmetic and other uses
12/15/2005WO2005117810A1 External preparation for the skin
12/15/2005WO2005117803A1 Process for producing edible oral administration preparation of aggregated substance-containing laminated film, and edible oral administration preparation of aggregated substance-containing laminated film
12/15/2005WO2005117755A2 Devices, systems and methods for treating sinusitius
12/15/2005WO2005117585A1 Mixed co-crystals and pharmaceutical compositions comprising the same
12/15/2005WO2005102359A8 Liposomal formulations of anthracycline agents and cytidine analogs
12/15/2005WO2005097228A3 Coating compositions for bioactive agents
12/15/2005WO2005097102A3 Method to treat chronic heart failure and/or elevated cholesterol levels
12/15/2005WO2005084648A8 Pharmaceutical compositions comprising candesartan cilexetil
12/15/2005WO2005079754A3 Layered silicate nanoparticle-polymer composite medical articles
12/15/2005WO2005079506A3 Systemic immune activation method using nucleic acid-lipid complexes
12/15/2005WO2005065318A3 Effervescent oral opiate dosage form
12/15/2005WO2005058288A3 Antimicrobial article with diffusion control layer
12/15/2005WO2005039501A3 Immunogenic composition and method of developing a vaccine based on fusion protein
12/15/2005WO2005035088A3 Method for preparing small spherical by controlled phase separation
12/15/2005WO2005027774A3 Method and apparatus for preventing allergies
12/15/2005WO2005018697A3 Active agent delivery systems, including a single layer of a miscible polymer blend, medical devices, and methods
12/15/2005WO2005009371A3 Ultra thin film transdermal/dermal or transmucosal/mucosal delivery system
12/15/2005WO2004089309A3 Conposition and methods for inhibiting fungal growth and transference
12/15/2005WO2004064787A3 Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
12/15/2005WO2004062616A3 Method of treating cognitive decline due to sleep deprivation and stress
12/15/2005WO2004000211A3 Improved compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
12/15/2005US20050277912 Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations
12/15/2005US20050277739 Novel temperature and pH sensitive copolymers
12/15/2005US20050277691 Pravastatin pharmaceutical formulations and methods of their use
12/15/2005US20050277657 Method of protection of biologically active essential oils and pharmaceutical composition for weight control and enhance fat burning in adults, adolescents and children
12/15/2005US20050277641 Nitrogen compounds such as 4-[[4-[[2,6-dibromo-4-(1-methylethyl)phenyl]amino]-1,3,5-triazin-2-yl]amino]benzonitrile, used for prophylaxis of viral diseases such as human immunodeficiency virus
12/15/2005US20050277611 Cationic cardiolipin analoges and its use thereof
12/15/2005US20050277609 Immunostimulatory nucleic acid molecules
12/15/2005US20050277604 Immunostimulatory nucleic acid molecules
12/15/2005US20050277585 Combinations of immunosupressive agents for the treatment or prevention of graft rejections
12/15/2005US20050277584 Pharmaceutical compositions comprising cyclosporins
12/15/2005US20050276974 Phospholipid-free, having a D50 particle size of less than 500 nm, andhaving a surface stabilizer; improved pharmacokinetic profiles and reduced fed/fasted variability
12/15/2005US20050276868 Bicarbonate-based peritoneal dialysis solutions
12/15/2005US20050276867 Stabilized compositions comprising a therapeutically active agent and an oxidizing preservative
12/15/2005US20050276862 Iron sequestering antimicrobial composition
12/15/2005US20050276861 Ex-vivo application of solid microparticulate therapeutic agents
12/15/2005US20050276859 Preparation of biodegradable, biocompatible microparticles containing a biologically active agent
12/15/2005US20050276856 Non-aqueous single phase vehicles and formulations utilizing such vehicles
12/15/2005US20050276855 Composition and method using local application of lipophilic lathyrogens sustained release formulations
12/15/2005US20050276854 Bioimplant formulation
12/15/2005US20050276853 Chronotherapeutic dosage forms and methods of treatment using chronotherapy
12/15/2005US20050276852 Sustained release formulations of guaifenesin and additional drug ingredients
12/15/2005US20050276851 Sustained release aminopyridine composition
12/15/2005US20050276850 Controlled release sodium valproate formulation
12/15/2005US20050276849 Sustained release dosage forms
12/15/2005US20050276848 Sustained release neutralized divalproex sodium
12/15/2005US20050276847 Oral delivery system
12/15/2005US20050276846 Biodrug and stabilizing carbohydrate for pulmonary administration; storage stability; e.g. insulin and trehalose
12/15/2005US20050276845 Insulin stabilized with a sugar alcohol; storage stability; pulmonary administration
12/15/2005US20050276844 Bioavailable compositions of metaxalone and processes for producing the same
12/15/2005US20050276843 An aerosol drug delivery device containing PTH, cyclodextrin, and didecanoylphophatidylcholine that provides droplets of 25 to 700 microns in size; improved bioavailability; osteoporosis
12/15/2005US20050276842 Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
12/15/2005US20050276841 Biodegradable drug-polymer delivery system
12/15/2005US20050276837 Controlled release bioactive agent delivery device
12/15/2005US20050276836 Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
12/15/2005US20050276824 Pharmaceutical emulsions for retroviral protease inhibitors
12/15/2005US20050276823 Methods and compositions for preventing oxidative degradation of proteins
12/15/2005US20050276798 with a histidine buffer and maltose; anti-HIV; higher concentrations, are storage stable, compatible with lyophilization, and safe to administer by intravenous injection
12/15/2005US20050276789 Immunostimulatory oligonucleotides and uses thereof
12/15/2005US20050276783 Polypeptides with the capacity to entrap drugs and release them in a controlled way
12/15/2005US20050276760 Tooth for whitening products and methods of making the same
12/15/2005US20050276759 for ballistic administration of a bioactive material to subcutaneous and intradermal tissue, delivery vehicle being sized and shaped for penetrating the epidermis; vehicle further comprises a stabilizing polyol glass, in particular, trehalose
12/15/2005US20050275621 Ergonomic pointing device
12/15/2005US20050274833 using a template to prepare high aspect ratio nanomaterials from spherical nanomaterials useful for oxides, nitrides, carbides, borides, metals, alloys, chalcogenides, and other compositions
1 ... 1710 1711 1712 1713 1714 1715 1716 1717 1718 1719 1720 1721 1722 1723 1724 1725 1726 1727 1728 1729 1730 ... 2991